结果：再灌注治疗是急性ST段抬高心梗治疗的主要方法。
Results: Reperfusion treatment was the major methods on non-ST-elevation acute coronary infarction.
CRUSADE入选包括高危不稳定性心绞痛和非ST段抬高心梗患者。
The CRUSADE initiative included high-risk patients with unstable angina and non–ST-segment elevation myocardial infarction (NSTEMI).
结论：再灌注治疗可以降低急性ST段抬高心梗的住院死亡率，减少住院不良事件的发生。
Conclusion: Reperfusion treatment may reduce the mortality of non-ST-elevation acute coronary infarction and the incidence of events in hospital.
直接经皮冠状动脉介入应该成为肾衰并s T段抬高急性心梗患者再灌注的首选治疗吗？
Should Primary Percutaneous Coronary Intervention Be the Preferred Method of Reperfusion Therapy for Patients With Renal Failure and ST-Elevation Acute Myocardial Infarction?
直接经皮冠状动脉介入应该成为肾衰并s T段抬高急性心梗患者再灌注的首选治疗吗？
Should Primary Percutaneous Coronary Intervention Be the Preferred Method of Reperfusion Therapy for Patients With Renal Failure and ST-Elevation Acute Myocardial Infarction?
应用推荐